Anticoagulation

For stroke prevention in atrial fibrillation, use a DOAC rather than warfarin in most patients. Select warfarin instead when the patient has moderate-to-severe mitral stenosis or a mechanical heart valve. PubMedPubMedAnticoagulation Safety - StatPearls - NCBI Bookshelf - NIH Mechanical valves require lifelong anticoagulation, and DOACs have not been approved for this indication. PubMed+1PubMedINTRODUCTION - Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism - NCBI BookshelfPubMedDOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives

For acute proximal DVT or PE, initiate therapeutic anticoagulation and treat for at least 3 months. Obtain baseline complete blood count, renal function, hepatic function, PT, and aPTT, but do not delay anticoagulation while awaiting these results; review abnormalities within 24 hours of starting interim therapeutic therapy. nice org uknice org ukVenous thromboembolic diseases: diagnosis, management ... - NICE At the 3-month decision point, weigh recurrence risk against bleeding risk and patient preference rather than treating anticoagulation as a cure for VTE. CDC+1CDC[PDF] NIH Public Access - CDC Stacksnice org ukVenous thromboembolic diseases: diagnosis, management ... - NICE

Choose warfarin rather than rivaroxaban for thrombotic antiphospholipid syndrome. In a randomized comparison, rivaroxaban 20 mg daily did not meet noninferiority versus vitamin K antagonist therapy, and recurrent arterial thrombosis and stroke were more frequent with rivaroxaban. ACCACCRivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome - American College of Cardiology This concern is greatest after arterial thrombosis and supports avoiding DOAC substitution in this phenotype. PubMed+1PubMedPractical Recommendations for Anticoagulation in Patients With ...ACCRivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome - American College of Cardiology

Cirrhosis is associated with thrombotic as well as bleeding risk. In Child-Pugh A or B cirrhosis with atrial fibrillation, use standard-dose DOAC therapy according to cardiology guidance used in patients without liver disease. ScienceDirectScienceDirectAnticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH In Child-Pugh C cirrhosis, evidence is insufficient to define the benefit-risk balance of anticoagulation for atrial fibrillation; avoid assuming that an elevated baseline INR provides protection from thrombosis. ScienceDirectScienceDirectAnticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH

For cirrhosis-associated portal vein thrombosis, anticoagulate symptomatic PVT. Consider anticoagulation for asymptomatic PVT that is progressing, and continue extended therapy in liver-transplant candidates with PVT. ScienceDirectScienceDirectAnticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH This separates incidental stable PVT from symptomatic or progressive disease in which preventing extension or preserving transplant options changes management. ScienceDirectScienceDirectAnticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH

For cancer-associated thrombosis, LMWH and DOACs are preferred treatment strategies, but selection requires an active review of anticancer-drug interactions, platelet count, and bleeding vulnerability. ScienceDirectScienceDirectHow to manage anticoagulation for cancer-associated thrombosis ... Active cancer increases major bleeding risk during anticoagulation by approximately twofold, so repeat the bleeding-risk assessment when chemotherapy, thrombocytopenia, renal impairment, invasive procedures, or antiplatelet therapy are introduced. ScienceDirect+1ScienceDirectHow to manage anticoagulation for cancer-associated thrombosis ...CDC[PDF] NIH Public Access - CDC Stacks

Do not use INR to quantify DOAC effect. If a clinically consequential question exists—serious bleeding, suspected overdose, thrombosis while treated, renal or hepatic insufficiency, or a potential drug interaction—order an assay matched to the agent. NatureNatureBeing precise with anticoagulation to reduce adverse drug reactions For dabigatran, diluted thrombin time and ecarin clotting time are sensitive and respond linearly across therapeutic plasma concentrations. NatureNatureBeing precise with anticoagulation to reduce adverse drug reactions

For unfractionated heparin, use the institutionally validated aPTT or anti-Xa monitoring protocol rather than interpreting a single result without clinical context. A therapeutic anti-Xa range of 0.5 to 1.2 IU/mL is cited, but major bleeding can occur despite a therapeutic aPTT; older age, female sex, lower weight, renal dysfunction, recent surgery or trauma, hepatic dysfunction, malignancy, low baseline hemoglobin, and concomitant antithrombotic therapy increase risk. NatureNatureBeing precise with anticoagulation to reduce adverse drug reactions

When considering thrombophilia evaluation after VTE, do not test after a provoked DVT or PE. If an unprovoked DVT or PE is being considered for anticoagulation discontinuation, consider antiphospholipid antibody testing; anticoagulants can affect the assays, so obtain specialist input on timing and interpretation. nice org uknice org ukVenous thromboembolic diseases: diagnosis, management ... - NICE

For dabigatran-associated bleeding requiring reversal, use idarucizumab, the specific reversal agent for dabigatran. NEJM+1NEJMReversal of Direct Oral Anticoagulants | NEJM ClinicianNEJMAntidotes for Anticoagulation Reversal Continue observation after initial reversal when clinically indicated because delayed rebound of dabigatran anticoagulant effect can occur. NEJMNEJMAntidotes for Anticoagulation Reversal A drug-specific dabigatran assay, when rapidly available, can help characterize residual anticoagulant effect, but reversal decisions in severe bleeding should not depend on an assay result that delays hemostatic treatment. NatureNatureBeing precise with anticoagulation to reduce adverse drug reactions

For apixaban- or rivaroxaban-associated major bleeding requiring urgent reversal, use andexanet alfa, which is approved for these direct factor Xa inhibitors. NEJM+1NEJMReversal of Direct Oral Anticoagulants | NEJM ClinicianNEJMAntidotes for Anticoagulation Reversal Andexanet is an intravenous agent that binds direct factor Xa inhibitors with high affinity. nice org uknice org uk[PDF] NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE - NICE Do not substitute an agent-specific antidote across mechanism classes: idarucizumab targets dabigatran, whereas andexanet targets direct oral factor Xa inhibitors. NEJM+1NEJMReversal of Direct Oral Anticoagulants | NEJM ClinicianNEJMAntidotes for Anticoagulation Reversal

After bleeding control, reassess the original thrombotic indication before deciding whether and when to resume anticoagulation. The early treatment period carries the greatest bleeding-related complication risk, particularly within the first 3 to 6 months, but interruption also restores the patient's underlying thrombotic risk. PubMed+1PubMedAnticoagulation Safety - StatPearls - NCBI Bookshelf - NIHCDC[PDF] NIH Public Access - CDC Stacks

At 3 months after proximal DVT or PE, determine whether treatment stops or continues by reassessing whether the event was provoked, whether recurrence risk remains high, and whether bleeding risk has changed. nice org uk+1nice org ukVenous thromboembolic diseases: diagnosis, management ... - NICECDC[PDF] NIH Public Access - CDC Stacks Unprovoked proximal DVT, recurrent DVT, and PE historically favor treatment beyond 6 months when major bleeding risk is not prohibitive, but the duration decision should remain individualized. PubMed+1PubMedINTRODUCTION - Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism - NCBI BookshelfCDC[PDF] NIH Public Access - CDC Stacks

Assess for factors that alter anticoagulant exposure or safety at each new illness, medication change, hospital admission, and planned procedure: declining renal or hepatic function, potential drug-drug interactions, active cancer therapy, thrombocytopenia, and concurrent antiplatelet or thrombolytic treatment. Nature+1NatureBeing precise with anticoagulation to reduce adverse drug reactionsScienceDirectHow to manage anticoagulation for cancer-associated thrombosis ... For VKA therapy, INR remains the pharmacodynamic monitoring tool; for DOACs, reserve drug-level or activity testing for clinically consequential scenarios. NatureNatureBeing precise with anticoagulation to reduce adverse drug reactions

Do not stop oral anticoagulation solely because of repetitive falls when its thromboembolic indication remains strong. Instead, identify modifiable bleeding risks and reassess net clinical benefit, particularly as age, cancer status, renal function, and concomitant antithrombotics evolve. PubMed+1PubMedPractical Recommendations for Anticoagulation in Patients With ...CDC[PDF] NIH Public Access - CDC Stacks